FDA mulls compounding for peptides previously flagged over safety risks BioSpace BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters PBS News FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures Pittsburgh Post Gazette The wellness world is eager for RFK Jr.'s promised move on peptides : NPR Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law